Drug Industry

Jacintha Shenton, Imein Bousnina, Michael Oropallo, et al. Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment. Drug Discovery Today. 2025;30(4):104328. doi:10.1016/j.drudis.2025.104328

Lorna Ewart, Adrian Roth. Opportunities and challenges with microphysiological systems: a pharma end-user perspective. Nature Reviews. Drug Discovery. 2021;20(5):327-328. doi:10.1038/d41573-020-00030-2

Uwe Marx, Takafumi Akabane, Tommy B. Andersson, et al. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 2020;37(3):365-394. doi:10.14573/altex.2001241

S. Vincent Rajkumar. The high cost of prescription drugs: causes and solutions. Blood Cancer Journal. 2020;10(6):71. doi:10.1038/s41408-020-0338-x

Jarrod Bailey, Michael Balls. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations. BMC Medical Ethics. 2019;20(1):16. doi:10.1186/s12910-019-0352-3

Kathy Archibald, Katya Tsaioun, J. Gerry Kenna, Pandora Pound. Better science for safer medicines: the human imperative. Journal of the Royal Society of Medicine. 2018;111(12):433-438. doi:10.1177/0141076818812783

Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012

Matthew M. Davis, Amy T. Butchart, John R. C. Wheeler, Margaret S. Coleman, Dianne C. Singer, Gary L. Freed. Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline. Vaccine. 2011;29(51):9414-9416. doi:10.1016/j.vaccine.2011.09.128